文献速递主动脉疾病

意大利多中心开窗Anaconda™支架治疗复杂腹主动脉瘤注册研究

The Italian Multicentre Registry of Fenestrated Anaconda™ Endografts for Complex Abdominal Aortic Aneurysms Repair.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2020-07-21

该前瞻性注册研究纳入2012至2018年127例近端瘤颈不适合标准EVAR的复杂腹主动脉瘤患者,采用开窗Anaconda™支架治疗。围手术期技术成功率87%,30天死亡率为4%,中位随访21个月,再干预率随时间上升,结论认为该支架对复杂腹主动脉瘤有效。

要点

  • 开窗Anaconda™支架治疗复杂AAA的围手术期技术成功率为87%。
  • 30天死亡率为4%,随访期间再干预率逐渐增加至18±5%。
  • 支架可重新定位和经肱动脉入路插管是处理复杂解剖的有用特性。

核心结论

  • 开窗Anaconda™支架治疗复杂腹主动脉瘤有效。

研究设计与样本

  • 前瞻性多中心注册研究,纳入2012至2018年127例近端瘤颈不适合标准EVAR的患者,来自49个意大利血管外科单位。
  • 患者平均年龄74±7岁,ASA分级II/III/IV分别为12/85/30例。
  • 动脉瘤类型包括近肾/肾旁AAA 83例、IV型胸腹AAA 13例、EVAR后Ia型内漏16例、短颈AAA 15例。

主要发现

  • 围手术期技术成功率为87%(111/127),发生5例Ia型内漏、6例III型内漏和6例内脏血管丢失。
  • 30天死亡率为4%(5/127)。
  • 中位随访21±16个月,6个月时发生1例Ia型内漏(5%),3年时发生1例III型内漏(4%)。
  • 6个月和3年时分别新增2例(3%)和5例(3%)内脏血管闭塞。
  • 30天、6个月和3年再干预率分别为5%、7%和18±5%。

关键数值与推荐

  • 使用1、2、3、4个开窗的配置分别为5、56、39、27例,共涉及342条内脏血管。
  • 35%(44/127)的病例术中重新定位支架,37%(128/342)的内脏血管经肱动脉入路插管。

临床怎么用

  • 对于近端瘤颈不适合标准EVAR的复杂腹主动脉瘤,可考虑使用开窗Anaconda™支架。
  • 支架可重新定位和经肱动脉插管的特性有助于处理复杂解剖。
  • 术后需密切随访内漏和内脏血管闭塞,必要时再干预。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim was to describe the outcomes of the Anaconda™ Fenestrated endograft Italian Registry for complex aortic aneurysms (AAAs), unsuitable for standard endovascular aneurysm repair (EVAR). METHODS: Between 2012 and 2018 patients with a proximal neck unsuitable for standard EVAR, treated with the fenestrated Anaconda™ endograft, were prospectively enrolled in a dedicated database. Endpoints were peri-operative technical success (TS) and evaluation of type Ia/b or 3 endoleaks (T1/3 EL), target visceral vessel (TVV) occlusion, re-interventions, and AAA related mortality at 30 days, six months, and later follow up. RESULTS: One hundred twenty seven patients (74 ± 7 years, American Society Anesthesiology (ASA) II/III/IV: 12/85/30) were included in the study in 49 Italian Vascular Surgery Units (83 juxta/para-renal AAA, 13 type IV thoraco-abdominal AAA, 16 T1aEL post EVAR, and 15 short neck AAA). Configurations with one, two, three, and four fenestrations were used in 5, 56, 39, and 27 cases, respectively, for a total of 342 visceral vessels. One hundred and eight (85%) bifurcated and 19 (15%) tube endografts were implanted. In 35% (44/127) of cases the endograft was repositioned during the procedure, and 37% (128/342) of TVV were cannulated from brachial access. TS was 87% (111/127): five T1EL, six T3EL (between fenestration and vessel stent), and six loss of visceral vessels (one patient with a Type Ia EL had also a TVV loss) occurred. Thirty day mortality was 4% (5/127). Two of the five T1EL resolved spontaneously at 30 days. The overall median follow up was 21 ± 16 months; one T1EL (5%) occurred at six months and one T3EL (4%) at the three year follow up. Another two (3%) TVV occlusions occurred at six months and five (3%) at three years. The re-intervention rate at the 30 days, six months, and three year follow up was 5%, 7%, and 18 ± 5%, respectively. CONCLUSION: The fenestrated Anaconda™ endograft is effective in the treatment of complex AAA. Some structure properties, such as the re-positionability and the possibility of cannulation from above, are specific characteristics helpful for the treatment of some complex anatomies.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Pini R, Giordano J, Ferri M, et al. The Italian Multicentre Registry of Fenestrated Anaconda™ Endografts for Complex Abdominal Aortic Aneurysms Repair. Eur J Vasc Endovasc Surg. 2020. PMID: 32709467. doi:10.1016/j.ejvs.2020.04.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。